Mouse Liver Proteomics Data Comparing 2-ME/DMSO and IAA Alkylation Methods

6.3 MB of proteomics data compares the quantitative performance of a 2-mercaptoethanol/DMSO workflow against conventional iodoacetamide treatment. Mouse liver proteomes were processed and analyzed via LC-MS/MS, showing improved peptide and protein quantification reproducibility. The dataset, authored by Arisa Suto and last updated in May 2026, includes results applied to ovarian clear cell carcinoma.

Use Cases

• Benchmarking cysteine alkylation methods based on the comparison of 2-ME/DMSO and IAA workflows.
• Evaluating quantitative reproducibility in proteomics based on reported peptide and protein coefficient of variation (CV) metrics.
• Analyzing protein sequence coverage improvements based on the reported 77% of proteins showing enhanced coverage.
• Investigating cisplatin-induced alterations in cancer models based on the application to ovarian clear cell carcinoma.

Strengths

• Includes specific performance metrics: 1.6- to 1.9-fold increase in cysteine-modified peptides and 77% of proteins with improved sequence coverage.
• Reports quantitative reproducibility improvements: peptide CV ≤ 20% increased from 61.4% to 86.1%, and protein CV ≤ 20% increased from 80.6% to 93.5%.
• Data is available in a structured XLSX format, facilitating analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset's 6.3 MB size suggests a relatively small scale.

Provenance

Source

figshare

Collection Method

Mouse liver proteomes processed with 2-ME/DMSO or IAA treatment, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.

Freshness

Last updated 2026-05-08 06:46:58; freshness should be verified.